Topic cluster
GLP-1 Drug Comparisons & Pipeline: Wegovy, Zepbound, Foundayo & Beyond
Patients comparing branded GLP-1s — or evaluating the newer oral and pipeline drugs — need side-by-side trial data, not marketing copy. This cluster collects the head-to-head comparisons (tirzepatide vs semaglutide), the Foundayo / orforglipron deep-dives, and the pipeline drug articles (CagriSema, retatrutide, survodutide, MariTide, ecnoglutide).
12 research articles in this cluster · last updated 2026-04-08
Tirzepatide vs Semaglutide: A Head-to-Head Look at SURMOUNT and STEP
What the SURMOUNT and STEP trial families actually tell us about which GLP-1 drug produces more weight loss, fewer side effects, and longer-lasting results.
Foundayo vs Wegovy vs Zepbound: 2026 Head-to-Head
Foundayo (orforglipron) is the first oral GLP-1 for weight loss, FDA-approved April 1, 2026. How does it stack up against Wegovy and Zepbound? Side-by-side: 17.2 mg labeled-dose Foundayo 11.1% vs STEP-1 Wegovy 14.9% vs SURMOUNT-1 Zepbound 20.9%, $25 vs $499 vs $449, daily pill vs weekly injection.
What Is Orforglipron (Foundayo)? Mechanism, Maker & Pronunciation
Orforglipron (brand name Foundayo) is the first oral GLP-1 pill approved for weight loss, made by Eli Lilly and FDA-approved on April 1, 2026. This is the foundational explainer: what it is, who makes it, how the small-molecule GLP-1 mechanism works, what it's used for, how it compares to injectable GLP-1s, what it costs, and how to pronounce it.
Foundayo (orforglipron) Approved: The First Once-Daily Oral GLP-1 Pill for Weight Loss
Eli Lilly's Foundayo (orforglipron) was approved by the FDA on April 1, 2026, becoming the first once-daily small-molecule oral GLP-1 receptor agonist approved for chronic weight management. We walk through the ATTAIN-1 trial data, the dosing, the $25-$149/month pricing, and how the oral pill compares to injectable semaglutide and tirzepatide.
Orforglipron (Foundayo) Side Effects: ATTAIN-1 Trial Rates
What the FDA Foundayo label and the ATTAIN-1 phase 3 trial actually report for orforglipron side effects — the GI rates, the boxed MTC warning, the pancreatitis and gallbladder signal, and how the oral pill compares to injectable Wegovy and Zepbound.
Wegovy vs Ozempic vs Zepbound vs Mounjaro: The GLP-1 Brand Name Cheat Sheet
Five brand names, three active ingredients, two drugs, one confusing market. We untangle which brand is which, which are identical products with different labels, which insurance covers what, and why 'is Zepbound the same as Mounjaro?' is the most-searched GLP-1 brand question.
Can You Take Phentermine With a GLP-1? The Combination Therapy Evidence and the Safety Concerns
Five hundred patients a month search 'can you take phentermine with semaglutide.' This is the evidence-based answer: there is no FDA approval for the combination, no randomized trial data on it, and real safety concerns about cardiovascular risk and stimulant exposure on top of GLP-1 therapy. Some obesity-medicine specialists do prescribe both, with monitoring. Here is the actual evidence and the risk framework.
Beyond Wegovy and Zepbound: Three Pipeline GLP-1 Drugs That Could Reach Approval in 2026-2027
Survodutide (Boehringer Ingelheim/Zealand), maridebart cafraglutide (MariTide, Amgen), and ecnoglutide (Sciwind/Pfizer) are the three most-watched GLP-1 pipeline drugs that aren't being made by Lilly or Novo. We walk through the verified phase 2 and phase 3 data on each, the mechanisms, and where they fit in the post-CagriSema, post-retatrutide landscape.
CagriSema REDEFINE: What Novo Nordisk's Amylin Combination Actually Showed
CagriSema (cagrilintide + semaglutide) is Novo Nordisk's next-generation amylin-GLP-1 combination injection. We walk through the REDEFINE 1 and REDEFINE 2 phase 3 trial results — 22.7% adherent weight loss in non-diabetic patients, 15.7% in patients with type 2 diabetes — and explain why the result missed the 25% target Novo had guided to but still beat semaglutide alone.
Retatrutide: What We Know About Lilly's Triple Agonist as TRIUMPH-4 Reads Out
Retatrutide is Eli Lilly's investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. The first phase 3 readout (TRIUMPH-4) reported 28.7% mean weight loss at the highest dose in adults with obesity and knee osteoarthritis. We walk through the published phase 2 data, the TRIUMPH-4 results, the open trials, and the new safety signal that emerged in the phase 3 program.
Berberine vs GLP-1s: What the Evidence Actually Shows About "Nature's Ozempic"
Berberine has been called "nature's Ozempic" on TikTok and in the supplement press. The peer-reviewed evidence is far narrower: a 2.07 kg average weight loss in a 12-RCT meta-analysis (Asbaghi 2020) versus 14.9% on semaglutide (STEP-1) and 20.9% on tirzepatide (SURMOUNT-1) — and an oral bioavailability under 1%. Here is the verified primary-source evidence.
What STEP-TEENS Showed: Semaglutide for Adolescents with Obesity
STEP-TEENS (Weghuber et al., NEJM 2022) is the trial that made Wegovy the first FDA-approved GLP-1 for adolescent obesity. 201 adolescents aged 12-17 randomized to weekly semaglutide or placebo for 68 weeks produced a 16.7-percentage-point separation in BMI change. Here's what the trial actually showed, what the AAP now recommends, and the long-term follow-up question that hasn't been answered yet.